Molecular Partners Ag (MOLN) Current Deferred Revenue (2020 - 2024)

Molecular Partners Ag (MOLN) has reported Current Deferred Revenue for 5 consecutive years, with $646889.2 the latest figure, recorded in Q2 2024.

• On a quarterly basis, Current Deferred Revenue fell 59.07% year-over-year to $646889.2 in Q2 2024; TTM through Jun 2024 was $646889.2, a 59.07% decrease from a year earlier, with the FY2023 full-year figure at $4.8 million, up 26.54% from the prior year.
• Current Deferred Revenue was $646889.2 for Q2 2024 at Molecular Partners Ag, down from $2.2 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $8.5 million in Q1 2022 and troughed at $646889.2 in Q2 2024.
• A 5-year average of $3.3 million and a median of $2.7 million in 2020 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue soared 277.89% in 2022 and plunged 88.21% in 2023, its largest moves.
• Over 5 years, Current Deferred Revenue stood at $3.3 million in 2020, then jumped by 131.01% to $7.5 million in 2021, then slumped by 49.73% to $3.8 million in 2022, then rose by 29.39% to $4.9 million in 2023, then slumped by 86.76% to $646889.2 in 2024.
• The last three Current Deferred Revenue figures came in at $646889.2 (Q2 2024), $2.2 million (Q1 2024), and $4.9 million (Q4 2023), per Business Quant data.